Cadrenal therapeutics raises $5.1 million via at-the-market facility

Ponte vedra, fla. , oct. 24, 2024 /prnewswire/ -- cadrenal therapeutics, inc., (nasdaq: cvkd) (the "company" or "cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin k antagonist (vka) designed to offer safer, superior chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced that is has raised gross proceeds of approximately $5.1 million through its at-the-market (atm) facility, selling an aggregate of 391,243 shares of common stock at a weighted average price of $13.15 per share.
CVKD Ratings Summary
CVKD Quant Ranking